Skip to main content
Wave Life Sciences Ltd. logo

Wave Life Sciences Ltd. — Investor Relations & Filings

Ticker · WVE ISIN · USY953081053 US Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US WVE

About Wave Life Sciences Ltd.

https://www.wavelifesciences.com/

Wave Life Sciences is a clinical-stage biotechnology company focused on developing RNA-based medicines to treat serious, genetically defined diseases. The company leverages its proprietary PRISM® platform, which utilizes a toolkit of RNA-targeting modalities and chemistry innovations to create stereopure nucleic acid therapies. Wave's objective is to deliver disease-modifying treatments for conditions with high unmet medical needs. Its development pipeline includes therapeutic candidates for both rare and common disorders, with programs targeting neurological conditions like Huntington's disease and Duchenne muscular dystrophy, as well as other diseases such as Alpha-1 antitrypsin deficiency and obesity.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report,” reporting Regulation FD disclosure and furnishing a press release as an exhibit. It does not contain substantive financial statements or serve as an annual/quarterly report, nor is it a proxy, dividend notice, management change, or other specific category. Therefore it is classified under Regulatory Filings (RNS), which covers miscellaneous SEC filings that don’t fit other categories.
2026-05-18 English
10-Q - Wave Life Sciences Ltd. (0001631574) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-28 English
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and includes a press release with financial results for the quarter ended March 31, 2026. It also references Item 7.01 "Regulation FD Disclosure" with a corporate presentation. The document states that the press release and presentation are furnished as exhibits and are not "filed" for purposes of Section 18, indicating this is an announcement rather than the full financial report itself. The document length is 4187 characters, which is relatively short and consistent with a current report announcing earnings results and providing a presentation. This matches the definition of an Earnings Release (ER) as it is the initial announcement of quarterly financial results with key highlights only, not a full interim or annual report. Therefore, the correct classification is Earnings Release (ER).
2026-04-28 English
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content focuses on announcing a press release about a hearing on a proposed redomiciliation and references a forthcoming definitive proxy statement related to the redomiciliation. It includes cautionary forward-looking statements and details about solicitation of proxies. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is primarily an announcement of an event and related filings, not the filings themselves. The mention of a proxy statement to be filed later indicates this is a regulatory announcement about upcoming shareholder voting materials. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-04-21 English
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or corporate changes. The content describes a corporate restructuring involving redomiciliation from a Singapore company to a Delaware corporation, including entry into a material definitive agreement and plans to file a proxy statement. It includes no financial statements or detailed financial analysis. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial report. It is a regulatory announcement of a significant corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-15 English
SCHEDULE 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)
Major Shareholding Notification
2026-03-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.